TEKMIRA (TKMRF): Der frühe Vogel fängt den Wurm...... - 500 Beiträge pro Seite

[Massel]

Erst die gute News mit der Bristol-Myers Squibb Zahlung und nun das:

http://www.marketwire.com/press-release/Tekmira-Pharmaceutic…

May 12, 2010 17:26 ET
Tekmira Pharmaceuticals Outlines Plans for a NASDAQ Listing

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 12, 2010) - Tekmira Pharmaceuticals Corporation (TSX:TKM), a leader in RNA interference (RNAi) therapeutics, announced today that it intends to apply to list its common shares on the NASDAQ stock market.

Dr. Mark J. Murray, Tekmira's President and CEO, said, "We anticipate that listing our common shares on NASDAQ will broaden Tekmira's exposure to leading North American healthcare investors. Many of our peers have securities listed in the United States and we believe doing so is a logical step in the evolution of Tekmira to be appropriately valued as a leader in the RNAi field."

"We are preparing to list our common shares on NASDAQ and believe we will be in a position to file the documentation necessary to initiate the listing process with the U.S. Securities and Exchange Commission and NASDAQ in the next few months," added Dr. Murray.

Listing of Tekmira's common shares on NASDAQ will be subject to a number of U.S. and Canadian regulatory requirements, including registration of the common shares with the U.S. Securities and Exchange Commission and a determination by NASDAQ that Tekmira has satisfied all applicable listing requirements.

Tekmira's clinical pipeline currently consists of its lead RNAi therapeutic product candidate ApoB SNALP, which is being developed as a treatment for high LDL cholesterol, or "bad" cholesterol. ApoB SNALP is scheduled to continue clinical evaluation later this year. Tekmira plans to file an investigational new drug (IND) application for its second product candidate, PLK1 SNALP, in order to initiate a Phase 1 human clinical trial in the second half of 2010. PLK1 SNALP is being developed as a treatment for cancer.

Tekmira has license or collaborative agreements with a number of leading biotechnology and pharmaceutical companies, including Alnylam Pharmaceuticals Inc., Merck & Co., Inc., Roche, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, and Pfizer.

About RNAi and SNALP

RNAi therapeutics have the potential to treat a broad number of human diseases by "silencing" disease-causing genes. The discoverers of RNAi, a gene-silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as "siRNAs", require delivery technology to be effective systemically. Lipid nanoparticles (LNPs) are one of the most widely used siRNA delivery approaches for systemic administration. Tekmira's SNALP (stable nucleic acid-lipid particles) technology is the leading class of LNPs being used in clinical development. SNALP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles which are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. SNALP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible. SNALP-based products have been reviewed by multiple FDA divisions for use in clinical trials. SNALP formulations comprise several lipid components that can be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering SNALP and LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

Forward-Looking Statements and Information

This press release contains "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian and U.S. securities laws (collectively, "forward-looking statements"). Forward-looking statements are generally identifiable by use of the words "believes", "may", "plans", "will", "anticipates", "intends", and similar expressions, and the negative of such expressions. Forward-looking statements in this news release include statements regarding Tekmira's plans to apply to list its common shares on NASDAQ and expectations regarding future product development, and other information that is not based on historical fact.

With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: Tekmira's ability to meet the listing requirements required by the NASDAQ, and the filing and declaration of effectiveness of a registration statement with the U.S. Securities and Exchange Commission (the "SEC"). While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic and market uncertainties, and contingencies. Additionally, there are known and unknown risk factors which could cause Tekmira's actual results to be materially different from any future results expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the possibility of Tekmira determining not to file an application to list its common shares with the NASDAQ; the possibility of Tekmira not meeting the minimum listing requirements of the NASDAQ; the possibility of the NASDAQ not accepting Tekmira's common shares for listing; the possibility of Tekmira determining not to file a registration statement with the SEC; and the possibility of the SEC not declaring such registration statement effective.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Information Form dated March 31, 2010 available at www.sedar.com. Tekmira disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or information contained herein to reflect future results, events or developments, except as required by law.
--------------------------------------------------------

Reaktion gestern: SK 1 CAD bei schönen Volumen von rund 300.000

Gruß
massel

[Massel]

TEKMIRA PHARMACEUTICALS CORPORATION

13.05.10 21:58 Uhr

1,22 CAD

+22,00 %

[Massel]

http://www.marketwatch.com/story/tekmira-reports-complete-pr…

Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi
Data Reflects High Potency and Utility of RNAi in Infectious Disease Applications

VANCOUVER, BRITISH COLUMBIA, May 28, 2010 (MARKETWIRE via COMTEX) -- Tekmira Pharmaceuticals Corporation /quotes/comstock/11t!tkm (CA:TKM 1.15, 0.00, 0.00%) , a leader in RNA interference (RNAi) therapeutics, today announced the publication of a series of studies demonstrating the ability of an RNAi therapeutic utilizing Tekmira's lipid nanoparticle technology, SNALP, to protect nonhuman primates from Ebola virus, a highly contagious and lethal human infectious disease.

Dr. Mark J. Murray, Tekmira's President and CEO, said, "These very striking data are the first demonstration that RNAi is efficacious in an otherwise lethal primate infectious disease setting. It is evidence of the profound potency which can be achieved with RNAi in that all of these animals survived what would have been a lethal dose of Ebola virus. We believe the results of these studies firmly establish that SNALP and RNAi therapeutics have broad utility in infectious diseases."

Tekmira conducted the studies in collaboration with leading infectious disease researchers from Boston University and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and funded in part by the U.S. government's Transformational Medical Technologies Initiative. The results, which have been published in the prominent medical journal The Lancet (Geisbert et al., "Post exposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof of concept study", The Lancet, Vol 375, May 29, 2010) describe antiviral activity of small interfering RNAs (siRNA) in SNALP targeting the Ebola virus (Ebola SNALP). When used to treat infected nonhuman primates, Ebola SNALP resulted in complete protection from an otherwise lethal dose of Zaire Ebola virus. For many years, the Zaire species of Ebola virus (ZEBOV) has been associated with periodic outbreaks of hemorrhagic fever in human populations with mortality rates reaching 90%. There are currently no treatments for Ebola or other hemorrhagic fever viruses.

Dr. Thomas W. Geisbert, Associate Director, National Emerging Infectious Diseases Institute, Boston University School of Medicine and one of Tekmira's collaborators, said, "We are excited to publish the first demonstration of complete protection against a lethal human infectious disease in nonhuman primates using RNAi. We believe this work justifies the immediate development of Ebola SNALP as an agent to treat Ebola infected patients either in outbreaks or accidental laboratory exposures."

Dr. Lisa E. Hensley, Chief Viral Therapeutics, Virology Division, USAMRIID and one of Tekmira's collaborators, said, "Over the past decade, we have evaluated numerous therapeutic approaches for the treatment of lethal viruses, such as Ebola. With the exception of siRNA delivered using Tekmira's SNALP technology, none of them have conferred complete protection to Ebola virus infected nonhuman primates. We look forward to continuing our work with Tekmira as they advance this promising therapeutic approach."

In the published studies, non-human primates were infected with a lethal dose of ZEBOV and were then treated with seven daily doses of Ebola SNALP. The Ebola SNALP therapeutic delivered three different siRNAs targeting three separate viral gene products thereby inactivating the virus in three different parts of its life cycle. The three siRNAs were encapsulated in Tekmira's proprietary SNALP delivery technology engineered for delivery to the cells where the Ebola virus is known to replicate. All of the nonhuman primates treated with the Ebola SNALP survived the infection and were shown to be free of ZEBOV virus infection within 14 days after inoculation with a lethal dose of ZEBOV virus.

"These studies also illustrate the ability of SNALP technology to efficiently encapsulate and deliver multiple siRNAs, in this case three, designed to silence different cellular targets. Silencing multiple targets contributes to the potency of the effect," added Dr. Murray.

Tekmira is continuing to work with its collaborators in evaluating RNAi therapeutics targeting lethal hemorrhagic fever viruses, including Ebola virus. Tekmira has also applied for additional U.S. government funding to continue this work.

Tekmira believes its SNALP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Tekmira's SNALP platform is being utilized in multiple preclinical and clinical trials by both Tekmira and its partners.

About RNAi and SNALP

RNAi therapeutics have the potential to treat a broad number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a natural gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as small interfering RNAs or "siRNAs" require delivery technology to be effective. Lipid nanoparticles (LNPs) are the most widely used siRNA delivery approaches for systemic administration. Tekmira's SNALP (stable nucleic acid-lipid particles) technology is the leading class of LNPs being used in clinical development. SNALP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles, which are safe and effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. SNALP formulations comprise several lipid components that can be adjusted to suit the specific application and are manufactured by a proprietary method, which is robust, scalable and highly reproducible. SNALP-based products have been reviewed by multiple FDA divisions for use in clinical trials. The systemic RNAi product candidates being advanced by Tekmira, Alnylam Pharmaceuticals and Roche employ SNALP technology.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering SNALP and LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

About Boston University

Established in 1873, Boston University School of Medicine is a leading academic and research institution, with an enrollment of nearly 630 students and more than 1,100 full and part-time faculty members. It is known for its programs in arthritis, cardiovascular disease, cancer, infectious diseases, pulmonary disease and dermatology, among others, and is one of the major biomedical research institutions in the United States. The School is affiliated with Boston Medical Center, its principal teaching hospital, and Boston Veterans Administration Medical Center. Along with Boston Medical Center and 15 community health centers, the School of Medicine is a partner in Boston HealthNet.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Material Command.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

Forward-Looking Statements and Information

This press release contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements are generally identifiable by use of the words "believes", "may", "plans", "will", "anticipates", "intends", "budgets", "could", "estimates", "expects", "forecasts", "projects" and similar expressions, and the negative of such expressions. Forward-looking statements in this news release include statements about RNAi and SNALP's ability to protect against Ebola virus, RNAi and SNALP's efficacy, potency and utility in treatment of infectious diseases, and the potential of RNAi and SNALP to treat a broad number of human diseases.

With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: the results in non human primates are indicative of the potential effect in humans, and the effectiveness of Tekmira's technology as a treatment for infectious diseases. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: clinical trials may not demonstrate safety and efficacy in humans or the drug candidates may fail in development or be delayed to a point where they do not become commercially viable.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's Annual Information Form dated March 31, 2010 available at www.sedar.com. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contacts:
The Equicom Group - Investors
Adam Peeler
416-815-0700 x 225
[e-mail]

[Massel]

Antwort auf Beitrag Nr.: 39.600.480 von Massel am 28.05.10 15:41:04

Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi

http://www.foxbusiness.com/story/markets/industries/health-c…

-----------------------------------------

Gruß
massel

[Massel]

Antwort auf Beitrag Nr.: 39.600.553 von Massel am 28.05.10 15:49:12

Dr. Thomas W. Geisbert, Associate Director, National Emerging Infectious Diseases Institute, Boston University School of Medicine and one of Tekmira's collaborators, said, "We are excited to publish the first demonstration of complete protection against a lethal human infectious disease in nonhuman primates using RNAi. We believe this work justifies the immediate development of Ebola SNALP as an agent to treat Ebola infected patients either in outbreaks or accidental laboratory exposures."

Dr. Lisa E. Hensley, Chief Viral Therapeutics, Virology Division, USAMRIID and one of Tekmira's collaborators, said, "Over the past decade, we have evaluated numerous therapeutic approaches for the treatment of lethal viruses, such as Ebola. With the exception of siRNA delivered using Tekmira's SNALP technology, none of them have conferred complete protection to Ebola virus infected nonhuman primates. We look forward to continuing our work with Tekmira as they advance this promising therapeutic approach."

NICHT VEERGESSEN: und im schön die Gelder fließen lassen.....

[Massel]

28.05.10 16:22 Uhr

1,45 CAD

+26,09 % [+0,30]

[Massel]

Damit die Tragweite der heutigen Nachricht besser deutlich wird, hier eine Deutsche Meldung zur dem bahnbrechenden Erfolg Tekmiras:

http://www.aerzteblatt.de/nachrichten/41391/RNA-Interferenz_…

Freitag, 28. Mai 2010
Medizin RNA-Interferenz stoppt Ebola-Viren

Für die Untersuchung der Ebola-Viren ist ein Hochsicherheitslabor notwendig /dpa
Boston – US-amerikanische Forscher haben mittels der RNA-Interferenz, einer natürlichen Abwehrreaktion gegen Viren, einen der tödlichsten Krankheitserreger besiegt. Im Lancet (2010; 375: 1896-1905) berichten sie, wie Affen vor dem Ausbruch der Erkrankung geschützt wurden.

Die 1976 in Zaire entdeckten Ebola-Viren sind Auslöser eines hämorrhagischen Fiebers mit einer Case-Fatality-Rate von bis zu 90 Prozent. In Zentralafrika hat es in den letzten Jahrzehnten immer wieder kleinere Epidemien gegeben und auch in den Hochsicherheitslabors von Industrieländern sind vereinzelt Infektionen aufgetreten, zuletzt im März 2009 nach einer Nadelstichverletzung bei einer Forscherin des Bernard-Nocht-Instituts für Tropenmedizin in Hamburg.

Die Forscherin überlebte – vielleicht nur dank eines experimentellen Impfstoffes, den kanadische Forscher entwickelt haben. Eine andere Therapie, ebenfalls von kanadischen Forschern entwickelt, wurde jetzt am Army Medical Research Institute of Infectious Diseases in Fort Detrick/Maryland erfolgreich getestet. Sie nutzt einen biologischen Abwehrmechanismus aus, über den die meisten eukaryoten Zellen (Pflanzen, Pilze und Tiere) verfügen und für deren Erklärung Andrew Fire und Craig Mello 2006 einen Nobelpreis erhielten.

zum Thema

* Abstract der Studie
* Pressemitteilung des US Army Medical Research Institute of Infectious Diseases

Mit der RNA-Interferenz werden gezielt Gene von Krankheitserregern ausgeschaltet (zum „Verstummen“ gebracht). Dies geht im Prinzip bei allen einzelsträngigen RNA-Viren, zu denen auch das Ebola-Virus gehört. Eine weitere Voraussetzung für einen sicheren Einsatz ist, dass sich die Gene stark von denen des Menschen unterscheiden, was beim Ebola-Virus bei der Erbinformation für das L-Protein der Fall ist.

Ohne dieses Enzym können sich die Viren nicht vermehren. Die US-Forscher haben Stücke dieses Gens (small interfering RNAs, siRNA) in Nanopartikel verpackt, die in der Lage sind, es in die infizierten Zellen zu transportieren. Dort kommt es dann zu einer körpereigenen Abwehr, die in der Lage ist, das tödliche Virus auszuschalten.

Den prinzipiellen Beweis für die Wirksamkeit erbrachten die Forscher in Experimenten an Rhesus-Affen. Eine erste Gruppe von drei Tieren wurde 30 Minuten nach der Exposition mit Ebolaviren mit den siRNA behandelt. Die Therapie wurde an drei weiteren Tagen wiederholt. In einer zweiten Gruppe wurden die Tiere an sechs aufeinander folgenden Tagen mit den “siRNAs” behandelt.

Zwei der drei Tiere der ersten Gruppe und alle vier Tiere der zweiten Gruppe überlebten die ansonsten auch bei Affen tödliche Infektion. Dabei wurde die Behandlung erstaunlich gut vertragen. Nur in der zweiten Gruppe kam es zu einem leichten Anstieg der Leberenzyme, die aber auch erstes Zeichen einer Ebola-Erkrankung gewesen sein könnten, wie die Gruppe um Thomas Geisbert von der Universität Boston vermutet.

Die Forscher kündigen weitere tierexperimentelle Studien an. Eine Zulassung ist derzeit noch nicht in Sicht. Man darf aber annehmen, dass im Fall einer Ebola-Epidemie auf den Wirkstoff zurückgegriffen würde. © rme/aerzteblatt.de

-----------

und die Firma hat immer noch eine mikrige MKPT......

massel

[Massel]

REALTIME 1,42 US

geht doch....

http://realtime.bigcharts.com/chart.asp?type=100style=45&siz…

gruß
massel

[Massel]

TEKMIRA PHARM CORP
01.06.10 17:23 Uhr

1,473 USD

+20,87 % [+0,2543]

[Massel]

Forbes Article:
An Ebola Cure?June 1, 2010 - 9:42 am
Steven Salzberg

Dr. Steven Salzberg is the Director of the Center for Bioinformatics and Computational Biology and the Horvitz Professor of Computer Science at the University of Maryland, College Park.

Ebola is one of the nastiest viruses known to man. Its victims suffer fevers, muscle weakness, and other symptoms that progress to severe bleeding, both internal and external, that eventually causes them to bleed to death. Various strains of Ebola virus have mortality rates ranging from 25% to 90%. Ebola was the subject of the frightening 1995 disaster movie, Outbreak, starring Dustin Hoffman, Rene Russo, and Morgan Freeman.

Last week, in what may be the biggest breakthrough of its kind in years, a group of scientists published results in The Lancet describing a completely new type of anti-viral treatment that appears to cure Ebola--at least it did in the four rhesus monkeys in which it was tested.

This is a breakthrough not only because it may give us a cure for an incredibly nasty virus, but also because the same method might work for other viruses, and because we have woefully few effective antiviral treatments. We can treat bacterial infections with antibiotics, but for most viruses, we have either a vaccine or nothing. And a vaccine, wonderful as it is, doesn’t help you after you’re already infected.

The scientists, led by Thomas Geisbert at Boston University, used a relatively new genomics technique called RNA interference to defeat the virus. Here’s how it works. First, a little background: the Ebola virus is made of RNA, just like the influenza virus. And like influenza, Ebola has very few genes - only 8. One of its genes, called L protein, is responsible for copying the virus. Two others, called VP24 and VP35, interfere with the human immune response, making it difficult for our immune system to defeat the virus.

Geisbert and his colleagues (including scientists from Tekmira Pharmaceuticals and USAMRIID) designed and synthesized RNA sequences that would stick to these 3 genes like glue. How did they do that? We know the Ebola genome’s sequence – it was sequenced way back in 1993. And we know that RNA sticks to itself using the same rules that DNA uses. This knowledge allowed Geisbert and colleagues to design a total of 10 pieces of RNA (called “small interfering RNA” or siRNA) that they knew would stick to the 3 Ebola genes. They also took care to make sure that their sticky RNA would not stick to any human genes, which might be harmful. They packaged these RNAs for delivery by inserting them into nanoparticles that were only 81-85 nanometers across.

In the key experiment, the scientists infected rhesus monkeys with a dose of Ebola that was 30,000 times greater than the normal fatal dose. They injected the siRNA treatments 30 minutes later, and again each day for 6 days. All the monkeys survived with no long-term effects.

When I read this story in The Lancet, my first reaction was: wow. A brand-new antiviral treatment, and against Ebola? In a commentary in The Lancet, Heinz Feldmann wrote that we are “in desperate need of approved countermeasures against Ebola-virus infections,” and called the new study a “milestone.” That’s putting it mildly.

Somehow, except for the UK Daily Mail, the major media outlets seem to have entirely missed this story, which I think is by far the biggest medical story of the week, if not the year. Ebola virus doesn’t get much attention (notwithstanding the 1995 movie about it), primarily because it occurs in central Africa. But air travel has made our world much smaller, and even a relatively isolated virus could easily get out of control.

There’s still a much work needed to turn the new Ebola treatment into an approved drug, but the prospect of a cure is suddenly very real, and the techniques used to create it are truly remarkable.

---------------------------

gruß
massel

[Massel]

Antwort auf Beitrag Nr.: 39.617.409 von Massel am 01.06.10 22:38:16

http://blogs.forbes.com/sciencebiz/2010/06/an-ebola-cure/

[Massel]

15.06.10 16:21 Uhr

1,73 CAD

+11,61 % [+0,18]

wie nennt man sowas nochmal ?

Gute Performance ??

[Massel]

TRADING HALT

http://www.marketwire.com/press-release/Tekmira-Awarded-Up-1…



JETZT KNALLT ES !!!



Gruß
massel

[homer65]

gw

[Massel]

http://www.marketwatch.com/story/tekmira-pharmaceuticals-rec…